Lung Cancer Therapy Makes Major Advances Lung Cancer Therapy Makes Major Advances

Dr Suresh Ramalingam discusses the findings presented at two recent meetings that offer new treatment options for patients with lung cancer.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

Nanomedicine, Ahead of Print.
Source: Future Medicine: Nanomedicine - Category: Nanotechnology Authors: Source Type: research
Co-drug delivery of regorafenib and cisplatin with amphiphilic copolymer nanoparticles: enhanced in vivo antitumor cancer therapy in nursing care. Drug Deliv. 2020 Dec;27(1):1319-1328 Authors: Zhou Z Abstract Cancers continue to be the second leading cause of death worldwide. Despite the development and improvement of surgery, chemotherapy and radiotherapy in cancer management, effective tumor ablation strategies are still in need due to high cancer patient mortality. Hence, we have established a new approach to achieve treatment-actuated modifications in a tumor microenvironment by using synergis...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
CONCLUSION: An ideal nano-carrier must have high loading efficiency, easily detectable, and must have stimuli's sensitive, site-specific drug release. The patent study explores new dimensions on MSNs synthesis by claiming new cost-effective templates and silica source, a more safe environment for synthesis, reducing synthesis steps, duration of reaction, effective loading of low solubility drugs by magnetized nanocarriers, pathogen-specific release and development of novel photoluminescent rechargeable MSNs under mild conditions. It's a challenging task for researchers to successfully translate their prototypes to industri...
Source: Recent Patents on Drug Delivery and Formulation - Category: Drugs & Pharmacology Tags: Recent Pat Drug Deliv Formul Source Type: research
CONCLUSIONS: Our study indicated that propofol inhibited A549 cell growth, accelerated apoptosis via the miR-21/PTEN/AKT pathway in vitro, suppressed NSCLC tumor cell growth, and promoted apoptosis in vivo. Our findings provide new implications for propofol in cancer therapy and indicate that propofol is extremely advantageous in surgical treatment. PMID: 32925348 [PubMed - in process]
Source: Anesthesia and Analgesia - Category: Anesthesiology Authors: Tags: Anesth Analg Source Type: research
A long time ago, metastatic brain tumors were often not treated and patients were only given palliative care. In the past decade, researchers selected those with single or 1-3 metastases for more aggressive treatments like surgical resection, and/or stereotactic radiosurgery (SRS), since the addition of whole brain radiotherapy (WBRT) did not increase overall survival for the vast majority of patients. Different studies demonstrated significantly less cognitive deterioration in 0-52% patients after SRS versus 85-94% after WBRT at 6 months. WBRT is the treatment of choice for leptomeningeal metastases. WBRT can lower the ri...
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Conclusions: Our data provided novel and further molecular rationale and preclinical data to support combination of metformin with EGFR TKIs to treat EGFR-mutant lung cancer patients, especially those with acquired resistance.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract Porous poly(cyclohexane-1,4-diyl acetone dimethylene ketal) (PCADK)/poly(d,l-lactide-co-glycolide) (PLGA) mixed-matrix porous microspheres loaded with doxorubicin (Dox) were successfully prepared, and PCADK/PLGA 2/8 was selected as the optimal mixed-matrix proportion. The optimal porous microspheres were characterized by a uniform spherical morphology, an obvious porous surface, an adaptive aerodynamic diameter (2.48 μm), good lung deposition and excellent encapsulation efficiency (77.22 %). The total release of Dox from PCADK/PLGA microspheres was 64.66 %, which was greater than the 46.31 % from the P...
Source: Colloids and Surfaces - Category: Biotechnology Authors: Tags: Colloids Surf B Biointerfaces Source Type: research
Publication date: Available online 27 August 2020Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Goknur Kara, Ayhan Parlar, Melike Cokol Cakmak, Murat Cokol, Emir Baki Denkbas, Feray Bakan
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
ConclusionNo significant differences in mean or magnitude of change in neurotoxicity scores were observed between treatment arms at any time point. However, patients in the placebo arm reported worsening neurotoxicity from baseline to 3 ‐months (M difference = −1.5,P = .045), compared to stable neurotoxicity in the veliparib arm (M difference = −0.2,P = .778). Weakness was the most common treatment‐emergent (>50%) and moderate to severe (>16%) symptom reported, but did not differ between treatment arms. The proportion of adherence to oral therapy in the overall ...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hematology | Lung Cancer